Delta-like 3 protein (DLL3) is an atypical Notch ligand induced by the neuroendocrine transcription factor, ASCL-1. DLL3 is expressed on the cell membrane and in the cytoplasm of tumor cells.

2024年11月19日 · In this study, we aimed to evaluate the prevalence and heterogeneity of mRNA and immunohistochemistry (IHC) expression of DLL3 at different subcellular compartments in 538 NEN from different...

2019年6月18日 · Delta-like ligand 3 (DLL3) is an inhibitory Notch ligand that is highly expressed in SCLC and other neuroendocrine tumors but minimally expressed in normal tissues. It is therefore being explored as a potential therapeutic target in SCLC.

We describe the landscape of DLL3 at the mRNA and protein levels across SCLC, large cell neuroendocrine carcinoma (LCNEC), and non-small cell lung cancer. Additionally, we explore its expression in extra-pulmonary NEN (EP-NEN) using a standardized DLL3 IHC assay. DLL3 expression is enriched in SCLC, LCNEC along with combined histology lung cancers.

2019年3月20日 · In nine cases, where mRNA data revealed DLL3 expression but immunohistochemistry (IHC) was negative, we developed probes to evaluate DLL3 mRNA expression in situ by RNA in situ hybridization (ISH); five of these nine cases demonstrated concordance between RNA ISH and IHC (fig. S6).

DLL3 EXPRESSION IN HEALTHY AND SCLC CELLS A large, multicenter study showed DLL3 expression in 85% of patients with SCLC (n=895/1,050), regardless of disease stage.9,* In this study, DLL3 positivity was defined as staining of ≥ 25% of tumor cells.9,†

Importantly, all patients with confirmed objective responses by investigator assessment were DLL3 Hi by immunohistochemistry (IHC). This early clinical experience highlights the significance of DLL3 assessment as a predictive biomarker for DLL3-targeted agents.

Delta like canonical Notch ligand 3 (DLL3) is an independent prognostic factor for invasive breast cancer (IBC) and represents a worse prognosis. DLL3 may be the messenger of the Notch and P53 signaling pathways. DLL3 may promote tumor progression ...

Here, we present data on the robustness of the VENTANA DLL3 (SP347) Assay in SCLC. Methods: Formalin-fixed, paraffin-embedded (FFPE) SCLC resection and biopsy specimens were used in a series of studies addressing robustness.

To identify the real-world utility of DLL3 as an SCLC therapeutic target, we performed the largest retrospective international noninterventional study to date to evaluate DLL3 prevalence in SCLC patients.